Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial | Zendy

Katharine Murkett | Zendy; Tobias Banaschewski | Zendy; Michel Lecendreux | Zendy; César Soutullo | Zendy; Alessandro Zuddas | Zendy; Ben Adeyi | Zendy; Shaw Sorooshian | Zendy; David Coghill | Zendy

Open Access

Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial

Author(s) -

Katharine Murkett,

Tobias Banaschewski,

Michel Lecendreux,

César Soutullo,

Alessandro Zuddas,

Ben Adeyi,

Shaw Sorooshian,

David Coghill

Publication year - 2014

Publication title -

neuropsychiatric disease and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.819

H-Index - 67

eISSN - 1178-2021

pISSN - 1176-6328

DOI - 10.2147/ndt.s68273

Subject(s) - methylphenidate , attention deficit hyperactivity disorder , medicine , psychiatry , randomized controlled trial , child and adolescent psychiatry , post hoc analysis , narcolepsy , pediatrics , modafinil

Following the approval of lisdexamfetamine dimesylate (LDX) in several European countries for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with an inadequate response to methylphenidate (MPH) treatment, the aim of the present analysis was to establish the response to LDX in subgroups of patients with different ADHD medication histories.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research